SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid heightened volatility as investors debate the impact of stalled regulatory clarity, with the community polarized between those accumulating on dips and those expressing frustration over stagnant price action. Many are actively tracking upcoming legislative developments and institutional activity, viewing the current price consolidation as a critical test of long-term support levels.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is surging following reports of a major, long-term data center lease deal with AI lab Anthropic, signaling a significant expansion in the company's high-performance computing infrastructure. The community is actively discussing the potential for further analyst price target upgrades as investors weigh the stock's transition from traditional bitcoin mining to a broader AI-focused data center play.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors debate the impact of the recent FTC lawsuit against the backdrop of an upcoming earnings report. While some in the community see the current dip as an opportunity to buy shares in a growth-focused telehealth platform, others are raising concerns about margin compression and the sustainability of their business model following the transition from compounding to branded medications.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is seeing significant momentum and investor interest driven by anticipation of a major anchor tenant announcement, with traders pointing to executive performance incentives that expire at the end of the month as a primary catalyst. Community discussion is split between bullish sentiment over the company's progress on infrastructure and power equipment milestones, and skepticism regarding its ability to secure binding contracts after previous volatility.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is trending as investors monitor recent silver price consolidation and its potential breakout supported by a weakening dollar and anticipation of future interest rate shifts. Community discourse is heavily focused on long-term accumulation, concerns over unsustainable national debt, and the metal's critical industrial role in AI and data center infrastructure.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is experiencing significant market volatility driven by investor anticipation surrounding the upcoming Phase 2 clinical trial results for its menopause drug, ABCL635. While the stock has seen aggressive buying and strong institutional interest following recent partnerships with major pharmaceutical firms, the community remains divided between those viewing the current pullback as a prime accumulation opportunity and others concerned about speculative rumors regarding trial outcomes.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors focus on the company's transformation into an AI infrastructure provider following its acquisition of Northern Data and its GPU-dense data centers. The community is actively debating the stock's potential for a short squeeze given its high short interest, while simultaneously weighing the impact of upcoming earnings and formal guidance on the company's valuation.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is seeing a major rally following a stellar Q1 report that highlighted massive backlog growth and strong revenue gains, fueled by critical demand for its natural gas power infrastructure in AI data center projects. Investors are aggressively betting on the company's role in supporting hyperscalers, with active community discussion centering on the sustainability of this growth, the strategic power deals with partners like Applied Digital, and the potential for a sustained short squeeze as the company continues to execute on its multibillion-dollar pipeline.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending as investors digest the recent release of highly positive clinical trial data, including an impressive 95% complete response rate in treatment-refractory patients. The community is actively discussing the stock's potential for a broader multi-indication platform, particularly for autoimmune diseases, while keeping a close watch on potential institutional accumulation and upcoming regulatory milestones.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as investors debate the impact of the company's aggressive Bitcoin treasury strategy and ongoing share dilution against the backdrop of potential regulatory developments like the Clarity Act. The community remains deeply polarized, with bulls positioning for a breakout driven by institutional adoption, while skeptics focus on the sustainability of the firm's debt and dividend obligations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +14.29% and +1.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +7.32% and +69.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues 

COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.

New Strong Buy Stocks for July 6th

BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.

Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why

COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.

Bull of the Day: Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) has quietly become one of biotech's strongest earnings stories.

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Collegium Pharmaceutical Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$27.20
Prev Close	$29.47
Open	$28.90
Dividend Yield	0.00%
50-Day Moving Average	$34.58
Beta	0.52
Avg. Volume	375,784.75
PE Ratio	22.04

52-Week High	$50.79
52-Week Low	$27.11
Market Capitalization	$959.41M
EPS (Annual)	$1.73
Price to Book	2.83
Revenue Per Employee	$1.85M

Feed

News

Sentiment

Earnings

Fundamentals

Info